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The purpose of this study was to determine activity of fosfomycin/gentamicin and daptomycin/gentamicin-containing PMMA
bone-cement against Staphylococcus aureus (MRSA, MSSA), Staphylococcus epidermidis, Enterococcus faecium (VRE), and E. coli
(ESBL; only fosfomycin). Test specimens of the bone cement were formed and bacteria in two concentrations were added one time
or repeatedly up to 96 h. All fosfomycin-containing cement killed ultimately allMSSA, Staphylococcus epidermidis, andE. coliwithin
24 h; growth of MRSA was suppressed up to 48 h. Activity of daptomycin-containing cement depended on the concentration; the
highest concentrated bone cement used (1.5 g daptomycin/40 g of powder) was active against all one-time added bacteria. When
bacteria were added repeatedly to fosfomycin-containing cement, growth was suppressed up to 96 h and that of MRSA and VRE
only up to 24 h.The highest concentration of daptomycin suppressed the growth of repeated added bacteria up to 48 h (VRE) until
96 h (MSSA, MRSA). In conclusion, PMMA bone cement with 1.5 g of daptomycin and 0.5 g of gentamicin may be an alternative
in treatment of periprosthetic infections caused by Gram-positive bacteria.
1. Introduction
Prosthetic joint infections are a serious complication in
arthroplastic surgery. A retrospective analysis of 450 clinics
in the Western part of Germany by using a questionnaire
revealed a prevalence of about 5-6% of septic arthroplastic
revisions related to the numbers of implant placements [1].
In USA, the Nationwide Inpatient Sample (Q4 2005–2010)
was analyzed for more than 200 thousand revisions of total
hip arthroplasties (THA) and for more than 300 thousand
revisions of total knee arthroplasties (TKA); periprosthetic
joint infection was the most common reason for revision of
TKA (25%) and the third most common reason for revision
of THA (15.4%) [2].
Prosthetic joint infections are mainly caused by Gram-
positive bacteria. In a recent study 33 clinical isolates were
analyzed; most staphylococci being resistant against methi-
cillin were identified [3]. Another study including 302 joints
of 272 patients found in each about 40–45% infections caused
by methicillin-sensitive and methicillin-resistant Gram-
positive species only and about 15% where Gram-negative
species (most prevalent Escherichia coli) were identified
[4]. Infections are biofilm-associated. Bacteria undergo a
transition from free-living, planktonic cells to sessile, surface-
attached cells; the biologic cycle includes initiation, matura-
tion,maintenance, and dissolution [5]. Aggregates of bacteria
are embedded in a self-produced polymer matrix and are
tolerant against innate and adaptive immune response as well
as against antibiotics being active against planktonic bacteria
[6].
The treatment of prosthetic joint infections is mostly
a two-stage revision by using polymethylmethacrylate
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(PMMA) bone cement as spacer [1, 2]. This standard
procedure for managing of infected TKAs and THAs consists
of debridement with hardware removal, local and systemic
antibiotic therapy, and delayed reimplantation [7].The added
antimicrobials should exhibit good antibacterial activity as
well as not interfering negatively with osteointegration [7].
Addition of gentamicin to PMMA has been proven since the
70s of the last century [8, 9]. Later erythromycin alone or
combined with colistin [10] and tobramycin [11] was applied.
The raising development of resistance implicated the search
for new agents. Silver nanoparticles were proved [12]. Among
antibiotics, vancomycin is used and exerts a sufficient activity
in joint fluid against methicillin-resistant S. aureus (MRSA)
and coagulase-negative staphylococci [13].
The aim of this study was to determine activity of fos-
fomycin/gentamicin and daptomycin/gentamicin-containing
bone cement against selected bacterial species to be known
as potential infectious agents in peri-implant orthopedic
infections. Fosfomycin and daptomycin were combined with
gentamicin.The chosen bacterial strains were defined strains
and exhibitedmainly a high degree of resistance. Experiments
were carried out up to 96 h with a daily removal of the
spent media and an addition of limited amount of a fresh
one simulating a decreasing amount of wound fluid. Beside
the determination of the antimicrobial activity of the eluates
the antibiofilm activity of the bone cement specimens was
proven.
2. Materials and Methods
2.1. Microorganisms. The activity of the bone cement and
their eluates was tested against two Staphylococcus aureus
strains (S. aureus DSM 2569 = ATCC 29213 (MSSA), S.
aureus DSM 13661 = ATCC 43300 (MRSA)), Staphylo-
coccus epidermidis DSM 8913, Enterococcus faecium DSM
13590 (VRE), and E. coli DSM 22311 (ESBL:SHV-1). All
the strains were obtained from the Leibniz Institute DSMZ
German Collection of Microorganisms and Cell Culture,
Braunschweig, Germany, being one of the largest biological
resource centers worldwide. S. aureus ATCC 29212 and S.
aureus ATCC 43300 are reference strains for testing antimi-
crobial resistance; S. epidermidis DSM 8913 was deposited
as an isolate of a prosthetic hip infection, and E. faecium
DSM 13590 and E. coli DSM 22311 were chosen because of
their defined resistance mechanisms to selected antibiotics.
Because of the natural resistance of E. coli to daptomycin,
the daptomycin/gentamicin-containing cement was excluded
from tests with that strain.
The strains were precultivated on tryptic-soy- (TS-) agar
(Oxoid, Basingstoke, GB).The overnight culture was adjusted
to 107 bacteria/ml.
2.2. MIC Determination and Determination of Inhibition
Zones. TheMIC values of gentamicin, fosfomycin, and dap-
tomycin against the included bacterial strains were deter-
mined by the microbroth dilution technique according to the
EUCAST recommendations [14] in independent replicates.
To relate the antimicrobial activity of the bone cement
eluates to those of the pure antibiotics, inhibition zones of
the single antibiotics and in certain mixtures against the used
bacterial strains were measured in addition. Dilution series
of the antibiotics (Sigma-Aldrich Chemie GmbH, Buchs,
Switzerland) were prepared from 3.13mg/ml fosfomycin and
from 1.56mg/l daptomycin and gentamicin. The mixtures
started from 1.56mg/ml, 2.34mg/ml, and 3.12mg/ml fos-
fomycin and from 0.78mg/ml, 1.56mg/ml, and 2.34mg/ml
daptomycin each mixed with 0.78mg/ml gentamicin. The
calculationwas based on the final concentration of antibiotics
in bone cement related to 10ml of elution media. Each
100 𝜇l of bacterial suspension (McFarland 0.5) was spread
on Mueller-Hinton agar plates (Oxoid). Meanwhile, 10 𝜇l of
the antibiotic solution was pipetted on a test disk (Oxoid)
which was placed on the agar plate. After an incubation time
of 18 h at 36∘C the inhibition diameter was measured and
the inhibition zone (distance between test disk and bacterial
growth) was recorded.
2.3. Bone Cement. Antibiotic-containing PMMA bone
cement and a PMMA bone cement reference (provided by
Heraeus Medical GmbH, Wehrheim) were included in the
tests. The bone cement was mechanically tested according
to ISO 5833. The powder of one unit consisted of 40.0 g of
polymer powder including zirconium dioxide as opaker and
benzoyl peroxide. In addition, the powder contained the
antibiotics listed in Table 1.
Test specimens were made of 5.0 g of powder and 2.5ml
of monomer. First a spatula was used to mix the two
components; finally round specimens (h = 10.0 ± 0.1mm, ⌀
= 25.0 ± 0.1mm) were formed by using predefined forms.
2.4. Activity of Bone Cement Eluates against Planktonic
Bacteria. Each of the three test specimens per cement was
prepared as described above. The specimens were added
to 10ml of phosphate buffered saline (PBS; Sigma-Aldrich
Chemie GmbH) and incubated at 36∘C for 24 h. Thereafter
the medium was removed and stored at −80∘C until assayed.
10 ml of PBS was added again to the bone cement specimens.
The procedure was repeated at 48, 72, and 96 h; however after
48 h, only 8ml and after 72 h only 6ml PBS were added.
The procedure for determining the antimicrobial activity
of the eluates was as described for antibiotic solution. Instead
of the antibiotic solution 10 𝜇l of the eluate was given on the
test disc.
2.5. Activity of Bone Cement against One-Time Added Bac-
teria. Bone cement test specimens were placed in tubes. A
suspension of 9.0ml of nutrient broth (brain-heart-infusion
broth; Oxoid) and of 1.0ml of sheep blood was added for
20min at 37∘C. Following that, bacteria were added in a
concentration of 106 and 103/10ml, respectively. After 24 h of
incubation at 37∘C and mixing of the suspension, 10 𝜇l was
taken and spread on TS-agar plates. Here, after 24 h of incu-
bation at 37∘C, the growth of bacteria was determined in a
semiquantitativemanner (no growth, up to 10 colonies, single
colonies still visible, and confluent growth). The remaining
broth was removed in a way that the test specimens were kept
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Table 1: Antibiotic content per unit test cement (40.0 g).
Cement Gentamicin content [g] Fosfomycin content [g] Daptomycin content [g]
1 0.5 1.0 —
2 0.5 1.5 —
3 0.5 2.0 —
4 0.5 — 0.5
5 0.5 — 1.0
6 0.5 — 1.5
7 0.5 — —
8 — — —
91 0.5 — —
101 — 1.0 —
111 — 1.5 —
121 — 2.0 —
131 — — 0.5
141 — — 1.0
151 — — 1.5
1These cement types were only included in experiments determining the activity of bone cement eluates.
wet. 10 ml of nutrient broth per tube was added again and the
tubes were incubated as before.
The procedure was analog after 48 h, 72 h, and 96 h;
however at 48 h only 8ml and at 72 h only 6ml of broth were
readded. This simulated the lower amount of wound fluid at
these respective times. At 96 h, the experiment was finished.
In one series each of the four test specimens was tested
against 103 and 106 bacteria, respectively. Experiments were
repeated; thus each of the eight single independent results was
obtained.
2.6. Activity of Bone Cement against Repeated Added Bacteria.
In this series including each of the five test specimens per
cement and strain, bacteria were added in a concentration
of 106 at the beginning. In the following days, every 103
of bacteria was added to the suspension again. The other
procedure was made as described above.
2.7. SEM Photographs. Exemplarily, SEM photographs were
taken after the one-time addition of S. aureus ATCC 44300
for 24 h. Samples were fixed in 2% glutaraldehyde in cacody-
late buffer for 30min, washed twice with cacodylate buffer,
and dehydrated using a graded ethanol series (15min for each
concentration). Following critical point drying, samples were
sputter-coated with gold and examined with a ZEISS LEO-
1530 Gemini (Carl Zeiss NTS GmbH) equipped with a field
emission electron gun at 7.5 keV.
2.8. Statistics. Most of the results are presented in a descrip-
tive way. In addition, Chi2 test was used to compare results
related to the different concentrations of the antibiotic as well
as between the antibiotics (only the highest concentrations).
3. Results
3.1. MIC Values and Inhibition Zones of Antibiotics. The
MIC values (determined in independent replicates with no
difference between the two tests) were in the range between
0.125𝜇g/ml and 128𝜇g/ml for fosfomycin. The highest MIC
was measured against E. faecium DSM 13590. MICs of dap-
tomycin were 1 𝜇g/ml except for E. faecium DSM 13590 with
8 𝜇g/ml. The MICs of gentamicin varied between 0.25 𝜇g/ml
(S. aureus ATCC 29213) and 64 𝜇g/ml (S. aureus ATCC
43300) (Table 2).
As expected, the inhibition zones of the antibiotics were
related to theMIC values.Mostly, gentamicin did not increase
the inhibition zones in comparison with single fosfomycin or
daptomycin (Table 3).
3.2. Activity of Bone Cement Eluates. Relating the inhibition
zones of bone cement eluates to those of the pure antibiotics
there was an activity of up to 2-3mg/ml fosfomycin after
24 h, it was decreasing to less than 0.5mg/l after 48 h.
The respective values for daptomycin were 0.2–0.4mg/ml
after 24 h and less than 0.05mg/ml after 48 h. The addition
of gentamicin prolonged antimicrobial activity of eluates
of fosfomycin-containing cement against S. aureus ATCC
29213, S. epidermidis DSM 8913, and E. coli DSM 22311 and
of daptomycin-containing cement against S. aureus ATCC
29213 and S. epidermidis DSM 8913 (Figures 1 and 2).
3.3. Bone Cement and One-Time Added Bacteria. Antibiotic-
free bone cement never suppressed growth of any bacteria at
any time-point.
All fosfomycin-containing cement killed ultimately all
S. aureus ATCC 23213 and E. coli DSM 22311 within 24 h,
independently if 103 or 106 bacteria were added. After
addition of 106 S. epidermidis DSM 8913 two test specimens
remained positively with low bacterial counts after 24 h (1
(12.5%) with 0.5 g gentamicin + 1.0 g fosfomycin and 1 (12.5%)
with 0.5 g gentamicin and 2.0 g fosfomycin); all other samples
were negatively tested. When 103 S. aureus ATCC 43300
were added to fosfomycin-containing PMMA cement only
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Table 2: Minimal inhibitory concentrations of antibiotics against test strains.
Gentamicin
(𝜇g/ml)
Fosfomycin
(𝜇g/ml)
Daptomycin
(𝜇g/ml)
S. aureus ATCC 29213 (MSSA) 0.25 4 1
S. aureus ATCC 43300 (MRSA) 64 8 1
S. epidermidis DSM 8913 8 0.125 1
E. faecium DSM 13590 (VRE) 16 128 8
E. coli DSM 22311 (ESBL:SHV-1) 2 4
Table 3: Inhibition zones antibiotics (distance (mm) between test disk and bacterial growth).
Strain GM (𝜇g/disc) Only GM Fosfomycin (𝜇g/disc) Daptomycin (𝜇g/disc)
3.9 7.8 15.6 31.2 2 5.9 7.8 23.4
S. aureus ATCC 29213
0 0 0 4 6 7 5 6.5 7.5 8.5
2 6 3.5 4 n.d. n.d. 4.5 5 n.d. n.d.
7.8 8.5 n.d. n.d. 6 7 n.d. n.d. 5.5 6.5
S. aureus ATCC 43300
0 0 0 0 0 4.5 5.5 6.5 7.5 8.5
2 0 0 0 n.d. n.d. 1 2 n.d. n.d.
7.8 0 n.d. n.d. 1 2 n.d. n.d. 2.5 4.5
S. epidermidis DSM 8913
0 0 5 7.5 10 13.5 7 7.5 9 10
2 0 13.5 15.5 n.d. n.d. 4.5 7 n.d. n.d.
7.8 0 n.d. n.d. 19.5 22 n.d. n.d. 7 8
E. faecium DSM 13590
0 0 0 0 1 2.5 3 4 5 6.5
2 0 0 8 n.d. n.d. 0 4 n.d. n.d.
7.8 1 n.d. n.d. 0 10 n.d. n.d. 2 5
E. coli DSM 22311
0 0 6 8.5 9.5 12 n.d. n.d. n.d. n.d.
2 6 3 4 n.d. n.d. n.d. n.d. n.d. n.d.
7.8 9.5 n.d. n.d. 5.5 12 n.d. n.d. n.d. n.d.
n.d.: not done; GM: gentamicin.
Discs of fosfomycin 31.2𝜇g/gentamicin 7.8 𝜇g and fosfomycin 7.8 𝜇g/gentamicin 2 𝜇g mimicking cement 2 g fosfomycin/0.5 g gentamicin.
Discs of fosfomycin 15.6 𝜇g/gentamicin 7.8 𝜇g and fosfomycin 3.9 𝜇g/gentamicin 2𝜇g mimicking cement 1 g fosfomycin/0.5 g gentamicin.
Discs of daptomycin 23.4𝜇g/gentamicin 7.8 𝜇g and daptomycin 5.9 𝜇g/gentamicin 2 𝜇g mimicking cement 1.5 g daptomycin/0.5 g gentamicin.
Discs of fosfomycin 7.8𝜇g/gentamicin 7.8 𝜇g and fosfomycin 2 𝜇g/gentamicin 2 𝜇g mimicking cement 0.5 g daptomycin/0.5 g gentamicin.
one of all tested samples became positive after 72 h and
96 h. After addition of 106 S. aureus ATCC 43300 growth
was suppressed up to 48 h; by tendency a concentration-
depending activity of the antibiotic was found after 72 h;
7 (87.5%) tests were positive after 1.0 g fosfomycin and 2
(25%) after 2.0 g fosfomycin. No growth of E. faecium DSM
13590 was found when 103 bacteria were added; however
after 106 bacteria 1–4 samples per group (12.5%–50%) were
positive after 24 h and 75–100% after 72 h independent of the
antibiotic concentration (Figure 3).
After addition of bacteria to daptomycin-containing bone
cement, all samples with 103 of staphylococci and E. faecium
DSM 13590 were completely negative or became negative
during the experiment. When 106 bacteria were added the
finding was the same for S. aureus ATCC 29213. For the
other included bacterial strains, the activity depended on
the daptomycin concentration; 1.5 g daptomycin killed all
bacteria whereas after 0.5 g daptomycin 3 (37.5%) to 7
(87.5%) samples were permanently positive at least from 48 h
(Figure 4). Differences between the three concentrations of
daptomycin were found for 106 added S. aureusATCC 43300,
S. epidermidis DSM 8913 at 48 h (𝑝 = 0.013, 𝑝 = 0.003), 72 h
(𝑝 = 0.002, 𝑝 = 0.003), and 96 h (𝑝 = 0.002, 𝑝 < 0.001), and
E. faecium DSM 13590 at 48 h (𝑝 = 0.032).
When comparing the highest concentration used of the
fosfomycin-gentamicin-containing bone cement with those
of the daptomycin-gentamicin-containing bone cement, dap-
tomycin was more effective against E. faecium DSM 13590
(24 h: 𝑝 = 0.021; 48 h: 𝑝 = 0.026; 72 h: 𝑝 = 0.002; 96 h:
𝑝 = 0.002).
3.4. Bone Cement and RepeatedAdded Bacteria. When bacte-
ria were added repeatedly to fosfomycin-containing cement,
growth of S. aureus ATCC 29213, S. epidermidis DSM 8913,
and E. coli DSM 22311 was suppressed up to 96 h and that of
S. aureus ATCC 43300 and of E. faecium DSM 13590 only up
to 24 h (Figure 5).
An antibiotic concentration dependent activity was vis-
ible after repeated addition of bacteria to daptomycin-
containing cement; growth was clearly suppressed by 1.5 g
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Figure 1: Inhibition zones (distance between test disk and bacterial growth, mm) of the eluates from 1.0 g, 1.5 g, and 2.0 g fosfomycin (FM),
0.5 g gentamicin (GM), and 1.0 g, 1.5 g, and 2.0 g fosfomycin/0.5 g gentamicin (FM/GM) containing bone cement obtained after 24 h, 48 h,
72 h, and 96 h against Staphylococcus aureus ATCC 29213 (MSSA), S. aureus ATCC 44300 (MRSA), S. epidermidis DSM 8913, Enterococcus
faecium DSM 13590 (VRE), and Escherichia coli DSM 22311 (ESBL:SHV-1).
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Figure 2: Inhibition zones (distance between test disk and bacterial growth, mm) of the eluates from 0.5 g, 1.0 g, and 1.5 g daptomycin (DM),
0.5 g gentamicin (GM), and 0.5 g, 1.0 g, and 1.5 g daptomycin/0.5 g gentamicin (DM/GM) containing bone cement obtained after 24 h, 48 h,
72 h, and 96 h against Staphylococcus aureusATCC 29213 (MSSA), S. aureusATCC44300 (MRSA), S. epidermidisDSM8913, and Enterococcus
faecium DSM 13590 (VRE).
daptomycin. The activity on E. faecium DSM 13590 lasted
24 h independent of the daptomycin concentration. After
48 h there was only an activity by 1.5 g daptomycin and after
96 h, all samples became positive (Figure 6). Daptomycin
concentration dependent differences were found for S. aureus
ATCC 43300 at 72 h (𝑝 = 0.005) and 96 h (𝑝 = 0.001), for S.
epidermidis at 72 h (𝑝 = 0.001), and for E. faeciumDSM 13590
at 48 h (𝑝 = 0.043).
When comparing the highest concentration used of the
fosfomycin-gentamicin-containing bone cement with those
of the daptomycin-gentamicin-containing bone cement,
those specimenswith daptomycinweremore effective against
S. aureusATCC43300 at 48 h (𝑝 = 0.002), at 72 h (𝑝 = 0.007),
and at 96 h (𝑝 = 0.002).
3.5. SEM Photographs. SEM photographs confirmed the
results for S. aureus ATCC 43300. Bacteria were clearly
damaged; however often they were of limited size in the pres-
ence of bone cement containing fosfomycin or daptomycin
(Figure 7).
4. Discussion
The developing antibiotic resistance implicates the search
for new therapeutic strategies. Preliminary experiments
using the same method as in the current study showed no
activity of bone cement containing gentamicin only against
MRSA strains including S. aureus ATCC 43300; a confluent
growth of bacteria was observed already every 24 h after
addition of the bacterial strains even in a concentration of
103 bacteria/10ml. In this in vitro study, the activities of
fosfomycin/gentamicin and daptomycin/gentamicin-loaded
bone cement as potential alternatives were tested against
selected bacterial strains. Mostly an alternative antibiotic is
combined with gentamicin. In vitro a longer lasting activity
is measured, for example, for combinations of vancomycin
or teicoplanin with gentamicin in comparison with the single
antibiotic [15].
The main focus of this in vitro study was a potential
antibiofilm activity of the bone cement. The clinical situation
immediately after surgery was imitated in two different ways.
In a first series, bone cement was exposed only one time to
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Figure 3: Number of samples (𝑛)with the different growth of bacteria in the nutrient broth after incubation with test specimens of 1.0 g (a, d,
g, j, m), 1.5 g (b, e, h, k, n), and 2.0 g fosfomycin (c, f, i, l, o)/0.5 g gentamicin-containing bone cement. Bacteria (Staphylococcus aureus ATCC
29213 (MSSA; (a), (b), (c)), S. aureus ATCC 44300 (MRSA; (d), (e), (f)), S. epidermidis DSM 8913 (g, h, i), Enterococcus faecium DSM 13590
(VRE; (j), (k), (l)), and Escherichia coliDSM 22311 (ESBL:SHV-1; (m), (n), (o))) were added at the beginning in a concentration of 103 (10𝐸3)
or 106 (10𝐸6) to 10ml of nutrient media. All controls (bone cement without antibiotics) showed confluent growth (not shown).
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Figure 4: Number of samples (𝑛)with the different growth of bacteria in the nutrient broth after incubation with test specimens of 0.5 g (a, d,
g, j), 1.0 g (b, e, h, k), and 1.5 g daptomycin (c, f, i, l)/0.5 g gentamicin-containing bone cement. Bacteria (Staphylococcus aureus ATCC 29213
(MSSA; (a), (b), (c)), S. aureus ATCC 44300 (MRSA; (d), (e), (f)), S. epidermidis DSM 8913 (g, h, i), and Enterococcus faecium DSM 13590
(VRE; (j), (k), (l))) were added at the beginning in a concentration of 103 (10𝐸3) or 106 (10𝐸6) to 10ml of nutrient media. All controls (bone
cement without antibiotics) showed confluent growth (not shown).
BioMed Research International 9
0
1
2n
3
4
5
48 72 9624
Time (h)
No growth
still visible
Single colonies
Confluent growth
<20 colonies
(a)
0
1
2n
3
4
5
48 72 9624
Time (h)
No growth
still visible
Single colonies
Confluent growth
<20 colonies
(b)
0
1
2n
3
4
5
48 72 9624
Time (h)
No growth
still visible
Single colonies
Confluent growth
<20 colonies
(c)
0
1
2n
3
4
5
48 72 9624
Time (h)
No growth
still visible
Single colonies
Confluent growth
<20 colonies
(d)
0
1
2n
3
4
5
48 72 9624
Time (h)
No growth
still visible
Single colonies
Confluent growth
<20 colonies
(e)
0
1
2n
3
4
5
48 72 9624
Time (h)
No growth
still visible
Single colonies
Confluent growth
<20 colonies
(f)
48 72 9624
Time (h)
0
1
2n
3
4
5
No growth
still visible
Single colonies
Confluent growth
<20 colonies
(g)
48 72 9624
Time (h)
0
1
2n
3
4
5
No growth
still visible
Single colonies
Confluent growth
<20 colonies
(h)
48 72 9624
Time (h)
0
1
2n
3
4
5
No growth
still visible
Single colonies
Confluent growth
<20 colonies
(i)
48 72 9624
Time (h)
0
1
2n
3
4
5
No growth
still visible
Single colonies
Confluent growth
<20 colonies
(j)
96724824
Time (h)
0
1
2n
3
4
5
No growth
still visible
Single colonies
Confluent growth
<20 colonies
(k)
48 72 9624
Time (h)
0
1
2n
3
4
5
No growth
still visible
Single colonies
Confluent growth
<20 colonies
(l)
48 72 9624
Time (h)
0
1
2n
3
4
5
No growth
still visible
Single colonies
Confluent growth
<20 colonies
(m)
48 72 9624
Time (h)
0
1
2n
3
4
5
No growth
still visible
Single colonies
Confluent growth
<20 colonies
(n)
48 72 9624
Time (h)
0
1
2n
3
4
5
No growth
still visible
Single colonies
Confluent growth
<20 colonies
(o)
Figure 5: Number of samples (𝑛)with the different growth of bacteria in the nutrient broth after incubation with test specimens of 1.0 g (a, d,
g, j, m), 1.5 g (b, e, h, k, n), and 2.0 g fosfomycin (c, f, i, l, o)/0.5 g gentamicin-containing bone cement. Bacteria (Staphylococcus aureus ATCC
29213 (MSSA; (a), (b), (c)), S. aureus ATCC 44300 (MRSA; (d), (e), (f)), S. epidermidis DSM 8913 (g, h, i), Enterococcus faecium DSM 13590
(VRE; (j), (k), (l)), and Escherichia coliDSM 22311 (ESBL:SHV-1; (m), (n), (o))) were added at the beginning in a concentration of 106/ml and
from 24 h daily in a concentration of 103. All controls (bone cement without antibiotics) showed confluent growth (not shown).
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Figure 6: Number of samples (𝑛)with the different growth of bacteria in the nutrient broth after incubation with test specimens of 0.5 g (a, d,
g, j), 1.0 g (b, e, h, k), and 1.5 g daptomycin (c, f, i, l)/0.5 g gentamicin-containing bone cement. Bacteria (Staphylococcus aureus ATCC 29213
(MSSA; (a), (b), (c)), S. aureus ATCC 44300 (MRSA; (d), (e), (f)), S. epidermidis DSM 8913 (g, h, i), and Enterococcus faecium DSM 13590
(VRE; (j), (k), (l))) were added at the beginning in a concentration of 106/ml and from 24 h daily in a concentration of 103. All controls (bone
cement without antibiotics) showed confluent growth (not shown).
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Figure 7: SEM photographs (20,000-fold magnification) of fosfomycin-containing bone cement (1.0 g fosfomycin/0.5 g gentamicin (a, b))
and of daptomycin-containing bone cement (0.5 g daptomycin/0.5 g gentamicin (c); 1.5 g daptomycin/0.5 g gentamicin (d)) with S. aureus
ATCC 44300 after 24 h of incubation.
bacteria mimicking a local infection, where infected tissues
are removed surgically and the remaining residing bacteria
were to be killed by the antibiotic. In the second series, a
constant spreading of bacteria in low numbers was suggested
in addition.The test specimenswere always placed in nutrient
brothwith 10%of sheep blood allowing coatingwith a protein
layer and thereafter biofilm formation. In all samples with
antibiotic-free test specimens a strong biofilm formation
was seen. The media were exchanged daily with decreasing
volumes of fresh media.
Fosfomycin, a phosphonic acid derivative, is a naturally
occurring antibiotic which displays a broad-spectrum activ-
ity against Gram-positive and Gram-negative bacteria by
inhibiting cell wall synthesis [16]. It is highly active against
MSSA, MRSA, and E. coli and exerts an intermediate activity
to VRE [17]. It is in clinical use in soft tissue infections,
osteomyelitis, abdominal infections, and urinary tract infec-
tions [16]. Reports about fosfomycin as an additive to resins
to be used in orthopedic surgery are rare. Several years ago,
addition of fosfomycin to a biodegradable composite was
suggested as treatment option [18]. Recently fosfomycin com-
bined with gentamicin was added to PMMA powder; eluates
from these cement types were highly active against MRSA
[19]. In the present study, fosfomycin exerted an excellent
activity against MSSA, S. epidermidis, and E. coli strains. The
used PMMA bone cement contained gentamicin in addition
to fosfomycin; the antimicrobial activity of the eluate was
higher and lasted longer against strains being sensitive to
both antibiotics when compared to fosfomycin alone. In a
foreign body animal model systemic applied fosfomycin was
highly active againstMRSA, but complete biofilm elimination
was only achieved when combined with rifampicin [20].
In our assays with bone cement test specimens, an activity
depending on the bacterial concentration was found; low
counts of bacteria were killed.
Daptomycin is a cyclic lipopeptide which targets Gram-
positive membranes by formation of ring-like pores [21]. It is
highly active against S. aureus, coagulase-negative staphylo-
cocci, Enterococcus faecalis, and E. faecium; during an eight-
year surveillance no significant increase or region variation
of resistance was observed [22]. In clinical trials, daptomycin
was found to be equal with standard antibiotics in severe skin
infections, bacteremia, and endocarditis caused by Gram-
positive bacteria [23]. A case report documented a successful
treatment of a recurrent prosthetic hip infection in a 70-year-
old female with a past history of MRSA infection by using
two-stage revision surgery with PMMA impregnated with
daptomycin and gentamicin [24].
As for fosfomycin, daptomycin was highly active against
a low count of bacteria. Both tests with eluates as well as
with bone cement specimens revealed that lowest concen-
trated daptomycin (0.5 g/40 g powder) was not as active as
the highest tested concentration of the antibiotic (1.5 g/40 g
powder) against MRSA, S. epidermidis, and E. faecium.
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This may be confirmative to a recent reports about release
profiles of PMMAbone-cement showing a continuous longer
release [25–27] and antimicrobial activity of daptomycin
when loaded with higher concentrations [26, 27]. If the
cement was loaded with daptomycin and gentamicin, release
profiles showed a prolonged antimicrobial activity in com-
parison with the single antibiotics. Daptomycin combined
with gentamicin exerted synergistic activity on intracellu-
lar S. aureus located intracellularly in osteoblasts [28]. An
increased in vitro antibiofilm activity of daptomycin together
with gentamicin in comparison with daptomycin only was
reported recently [29].This only other in vitro study focusing
on antibiofilm activity of daptomycin-containing cement
underlines an efficacy at least for 72 h when inoculated with
106 S. epidermidis [29].
A higher antibacterial activity was found for the cement
containing daptomycin/gentamicin than for those contain-
ing fosfomycin/gentamicin against Gram-positive bacteria.
Opposite to fosfomycin-containing cement, the used highest
concentrated daptomycin-containing cement clearly sup-
pressed the growth of the one-time added MRSA and VRE
strains up to 96 h. When the strains were added repeatedly,
daptomycin cement specimens showed a more prolonged
activity against the MRSA strain. However, as daptomycin
is inactive against Gram-negatives, fosfomycin might be a
treatment opportunity against ESBL strains which should be
verified in follow-up studies. The dependence of the activ-
ity of fosfomycin/gentamicin and daptomycin/gentamicin-
containing bone cement on the bacterial strainmay underline
a need for rapid microbiological diagnostics, for example,
by nucleic-acid based methods for rapid detection of ESBL
[30] and VRE [31] directly from clinical specimens, or as
described for identifying methicillin-resistant staphylococci
in prosthetic joint infections [32].
The tested PMMA bone cement was active against low
numbers of bacteria where biofilm formation was clearly
inhibited. This underlines necessity of mechanical debride-
ment of the wound area. Only an activity on biofilm forma-
tion can be anticipated. Experiments on established biofilms
showed biofilm eradication concentrations of S. aureus and
S. epidermidis biofilms as higher as 1024 𝜇g/ml daptomycin
recently [33]. The high resistance of bacteria within biofilms
is related to the slow or incomplete penetration of the matrix,
the physiologic response, for example, gene transfer, and the
development of persister cell populations [34].The small size
of different S. aureus cells after contact with PMMA bone
cement in SEM photographs may indicate the development
of persisters under antibiotic pressure. This well-known phe-
nomenon should not be neglected; it was recently shown for
S. aureus cells when exposed to 10-fold MIC of daptomycin
[35].
This in vitro study indicates daptomycin-containing
PMMA bone cement as a potential alternative in Gram-
positive prosthetic joint infections, whereas fosfomycin-
containing cement might be helpful in infections with ESBL
strains. Our study covered mainly aspects of suppression
of bacterial growth (antibiofilm activity) in the presence of
bone cement specimens considering a different volume of
wound fluid. Upcoming research should address in more
detail the release kinetics of the antibiotics from the cement, a
potential synergistic activity of the antibiotics, and a potential
development of resistance (persisters).
5. Conclusion
In summary, PMMA bone cement with higher concentra-
tions of daptomycin (1.5 g/40 g powder)may be an alternative
in treatment of selected periprosthetic infections by Gram-
positives. However follow-up research is necessary to evalu-
ate in more detail the release kinetics of the antibiotics, syn-
ergistic activity of the antibiotics, the possible development
of resistance (persisters), and the potential of fosfomycin-
containing PMMA cement to target ESBL strains.
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